Medidata Solutions Inc., a Dassault Systèmes brand and provider of clinical trial solutions to the life sciences industry, has been selected by Lexicon Pharmaceuticals Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades.   Medidata will enable Lexicon to accelerate patient enrollment and clinical trials for Lexicon’s AAK1...